AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Convatec Group PLC

Board/Management Information Jan 27, 2022

4959_rns_2022-01-27_8a92d237-f1d0-4d1d-aad0-27aadce70c57.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 8553Z

ConvaTec Group PLC

27 January 2022

ConvaTec Group Plc

Board Committee Changes

Reading, United Kingdom - 27 January 2022

ConvaTec Group Plc ("ConvaTec" or "the Company") is pleased to announce that Professor Constantin Coussios, a Non-Executive Director of the Company, has today been appointed as a member of the Company's Remuneration Committee and Nomination Committee.

This announcement is made in accordance with Listing Rule 9.6.11R (3).

Enquiries:

Analysts and Investors

Kate Postans, Vice President, Investor Relations                                           +44(0)7826 447 807

[email protected]

Media

Buchanan: Chris Lane                                                                                         +44(0)207 466 5000

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec Group Plc

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUBRRRUVUAUAR

Talk to a Data Expert

Have a question? We'll get back to you promptly.